RecruitingNCT07449715

Respiration From Pleth Validation


Sponsor

Philips Clinical & Medical Affairs Global

Enrollment

113 participants

Start Date

Feb 6, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

This observational clinical investigation evaluates the performance of respiratory rate derived from the plethysmography waveform (Respiration from Pleth, RfP) using Philips FAST Pulse Oximetry technology. Adult and pediatric inpatients will undergo noninvasive monitoring using age- and weight-appropriate SpO₂ sensors and capnography, with capnography serving as the reference standard. The study assesses accuracy, mean bias, precision, and time to first valid respiratory-rate value across continuous and spot-check conditions. No device outputs are used for clinical decision-making, and all procedures occur during a single study visit.


Eligibility

Min Age: 4 Years

Inclusion Criteria12

  • Adult Participants (defined as aged 18 years or older): Willing and able to understand and provide written informed consent
  • UK Pediatric subjects:
  • Aged 16 years and older willing and able to understand and provide written informed consent
  • Aged 4-15 years and their legal guardians willing and able to understand and provide written informed consent/assent
  • US Pediatric Participants: aged 4 to 17 years and their parent/legal guardian are willing and able to understand and provide written informed assent/consent
  • Participant weight is within intended use of at least one SpO2 sensor under test as time of enrollment.
  • M1191T, adult participants > 50 kg
  • M1192A, pediatric participants 15-50 kg
  • Nasal Alar Sensor, adult and pediatric participants ≥ 15 kg
  • M1194A, adult and pediatric participants > 40 kg
  • Willing and able to wear study devices for the entirety of study procedures
  • Undergoing regular spot-check measurements as per the site's standard of care

Exclusion Criteria11

  • Palliative patients
  • Patients with tremors, cardiac pacemakers, or known atrial fibrillation
  • Patients receiving oxygen supplementation at the time of study participation
  • Critically ill patients with severe physiological instability
  • Pregnant and/or lactating patients (self-reported)
  • Injury, wounds, and/or physical malformation of any sensor application site (e.g., fingers, nose, ear)
  • Self-reported severe contact allergies to standard adhesives, latex, and/or other materials found in pulse oximetry sensors
  • Unwillingness or inability to remove colored nail polish or artificial nails from the application site
  • Unwillingness or inability to remove foreign objects, such as nose and/or ear jewelry from sensor application sites
  • Nail fungus on application site
  • Severe dermatitis or hyperkeratosis (e.g. ichthyosis) at sensor application site

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEPhysiological Monitoring with SpO₂ Sensors and Capnography

Participants will undergo noninvasive physiological monitoring with commercially available Philips SpO₂ sensors (adult finger sensor M1191T; pediatric finger glove M1192A; nasal alar sensors 989803205391; adult/pediatric ear sensor M1194A) connected to Philips MP5 or PM6300 patient monitors configured with standard FAST Pulse Oximetry technology. A LoFlo Sidestream etCO₂ sensor (M2741A) with an adult or pediatric oral/nasal cannula (989803206671 or 989803206681) will be used to collect reference capnography waveforms. All monitoring is observational, and no device output is used for clinical decision-making.


Locations(2)

Duke University Hospital

Durham, North Carolina, United States

Ysbyty Gwynedd

Bangor, Gwynedd, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07449715